[
  {
    "ts": "2026-02-12T12:55:05+00:00",
    "headline": "Upstream Bio’s stock drops 47% on verekitug Phase II asthma data",
    "summary": "Investors pull away from Upstream as a twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing asthma exacerbations.",
    "url": "https://www.clinicaltrialsarena.com/news/upstream-bio-verekitug-phase-ii-valiant-severe-asthma-results/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "2fce59c7-cfbc-353b-9f3f-48a7e39981d0",
      "content": {
        "id": "2fce59c7-cfbc-353b-9f3f-48a7e39981d0",
        "contentType": "STORY",
        "title": "Upstream Bio’s stock drops 47% on verekitug Phase II asthma data",
        "description": "",
        "summary": "Investors pull away from Upstream as a twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing asthma exacerbations.",
        "pubDate": "2026-02-12T12:55:05Z",
        "displayTime": "2026-02-12T12:55:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/eb1a32634394c035e9091fab019630fb",
          "originalWidth": 2560,
          "originalHeight": 1638,
          "caption": "Upstream Bio will progress verekitug to a registrational Phase III trial in severe asthma. Image credit: Victoria Nevzorova via ShutterStock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G1tN3mSMkAyqECMVVSEDKw--~B/aD0xNjM4O3c9MjU2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/clinical_trials_arena_396/eb1a32634394c035e9091fab019630fb.cf.webp",
              "width": 2560,
              "height": 1638,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Gq0MHUKYI808MfjCWUcRIw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/eb1a32634394c035e9091fab019630fb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/upstream-bio-verekitug-phase-ii-valiant-severe-asthma-results/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/upstream-bio-stock-drops-47-125505864.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "UPB"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]